Harvard Bioscience Statistics
Share Statistics
Harvard Bioscience has 43.62M shares outstanding. The number of shares has increased by 0.5% in one year.
| Shares Outstanding | 43.62M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 40.16M |
| Failed to Deliver (FTD) Shares | 444 |
| FTD / Avg. Volume | 0.27% |
Short Selling Information
The latest short interest is 533.07K, so 1.22% of the outstanding shares have been sold short.
| Short Interest | 533.07K |
| Short % of Shares Out | 1.22% |
| Short % of Float | 1.33% |
| Short Ratio (days to cover) | 2.96 |
Valuation Ratios
The PE ratio is -66.46 and the forward PE ratio is 15.2.
| PE Ratio | -66.46 |
| Forward PE | 15.2 |
| PS Ratio | 2.02 |
| Forward PS | 0.8 |
| PB Ratio | 3.11 |
| P/FCF Ratio | 19.37 |
| PEG Ratio | n/a |
Enterprise Valuation
Harvard Bioscience Inc. has an Enterprise Value (EV) of 265.44M.
| EV / Earnings | -77.73 |
| EV / Sales | 2.36 |
| EV / EBITDA | 33.04 |
| EV / EBIT | 140.15 |
| EV / FCF | 22.65 |
Financial Position
The company has a current ratio of 1.85, with a Debt / Equity ratio of 0.5.
| Current Ratio | 1.85 |
| Quick Ratio | 0.92 |
| Debt / Equity | 0.5 |
| Total Debt / Capitalization | 33.35 |
| Cash Flow / Debt | 0.38 |
| Interest Coverage | 0.53 |
Financial Efficiency
Return on equity (ROE) is -0.05% and return on capital (ROIC) is 2.18%.
| Return on Equity (ROE) | -0.05% |
| Return on Assets (ROA) | -0.02% |
| Return on Capital (ROIC) | 2.18% |
| Revenue Per Employee | 287.08K |
| Profits Per Employee | -8.73K |
| Employee Count | 391 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 1.87 |
Taxes
| Income Tax | 859.00K |
| Effective Tax Rate | -0.34 |
Stock Price Statistics
The stock price has increased by -56.17% in the last 52 weeks. The beta is 1.31, so Harvard Bioscience 's price volatility has been higher than the market average.
| Beta | 1.31 |
| 52-Week Price Change | -56.17% |
| 50-Day Moving Average | 2.24 |
| 200-Day Moving Average | 2.95 |
| Relative Strength Index (RSI) | 49.09 |
| Average Volume (20 Days) | 162.61K |
Income Statement
In the last 12 months, Harvard Bioscience had revenue of 112.25M and earned -3.42M in profits. Earnings per share was -0.08.
| Revenue | 112.25M |
| Gross Profit | 66.07M |
| Operating Income | 1.89M |
| Net Income | -3.42M |
| EBITDA | 8.03M |
| EBIT | 1.89M |
| Earnings Per Share (EPS) | -0.08 |
Balance Sheet
The company has 4.28M in cash and 42.77M in debt, giving a net cash position of -38.49M.
| Cash & Cash Equivalents | 4.28M |
| Total Debt | 42.77M |
| Net Cash | -38.49M |
| Retained Earnings | -145.60M |
| Total Assets | 131.24M |
| Working Capital | 24.04M |
Cash Flow
In the last 12 months, operating cash flow was 14.03M and capital expenditures -2.31M, giving a free cash flow of 11.72M.
| Operating Cash Flow | 14.03M |
| Capital Expenditures | -2.31M |
| Free Cash Flow | 11.72M |
| FCF Per Share | 0.28 |
Margins
Gross margin is 5.89K%, with operating and profit margins of 169% and -304%.
| Gross Margin | 5.89K% |
| Operating Margin | 169% |
| Pretax Margin | -228% |
| Profit Margin | -304% |
| EBITDA Margin | 7.16% |
| EBIT Margin | 1.69% |
| FCF Margin | 10.44% |
Dividends & Yields
HBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3.76% |
| FCF Yield | 12.58% |
Analyst Forecast
Currently there are no analyst rating for HBIO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Nov 4, 2013. It was a forward split with a ratio of 1319:1000.
| Last Split Date | Nov 4, 2013 |
| Split Type | forward |
| Split Ratio | 1319:1000 |
Scores
| Altman Z-Score | -0.16 |
| Piotroski F-Score | 4 |